Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05526703
Other study ID # A30_14HT2209
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 28, 2022
Est. completion date October 2023

Study information

Verified date November 2022
Source Chong Kun Dang Pharmaceutical
Contact Yeonhwa Park, Project Leader
Phone 82-2-6373-0636
Email yeonhwa@ckdpharm.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date October 2023
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Subjects who are 19 years old or older. 2. Subjects who have voluntarily decided to participate in this clinical trial and signed ICF. Exclusion Criteria: 1. Subjects with a history of secondary hypertension or suspected secondary hypertension 2. Subjects who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period 3. Subjects with hypersensitivity or history of clinical trial drugs and similar drugs 4. Subjects who are required to administer a combination of prohibited drugs specified in this plan during the clinical trial participation period 5. Subjects with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening 6. Subjects who received other clinical trial drugs within 4 weeks of screening visit. 7. Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug 8. Subjects who are unable to participate in this clinical trial at the discretion of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
D064, D701, placebo of D012
Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
D012, placebo of D064, placebo of D701
Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in MSSBP Compare experimental group with comparator group 8 weeks after drug administrations
See also
  Status Clinical Trial Phase
Recruiting NCT03708601 - Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Not yet recruiting NCT05503953 - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS Phase 3
Completed NCT06395194 - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension Phase 3
Not yet recruiting NCT06418074 - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity N/A
Completed NCT02890173 - Study of CS-3150 in Patients With Essential Hypertension Phase 3
Completed NCT02944734 - Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension Phase 2
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Recruiting NCT01956786 - Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine Phase 2/Phase 3
Completed NCT02553512 - Helius in Hypertension-I: The UK Hypertension Registry N/A
Completed NCT01198249 - Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension Phase 1
Completed NCT01001572 - Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension Phase 3
Recruiting NCT00380289 - Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension N/A
Completed NCT00139698 - Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Phase 3
Completed NCT00288184 - Uric Acid in Essential Hypertension in Children Phase 2
Completed NCT01289886 - Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects Phase 1
Not yet recruiting NCT06041529 - Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Phase 4
Completed NCT04470830 - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
Completed NCT00758524 - A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension Phase 2
Recruiting NCT05109013 - Juvenile Essential Arterial Hypertension and Vascular Function
Completed NCT00741585 - Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment Phase 4